PPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome

[1]  J. Martínez,et al.  Interactions of the PPARγ2 Polymorphism with Fat Intake Affecting Energy Metabolism and Nutritional Outcomes in Obese Women , 2010, Annals of Nutrition and Metabolism.

[2]  G. Rosa,et al.  The Ala allele in the PPAR-gamma2 gene is associated with reduced risk of type 2 diabetes mellitus in Caucasians and improved insulin sensitivity in overweight subjects. , 2010, The British journal of nutrition.

[3]  M. Ricote,et al.  PPARs in the Renal Regulation of Systemic Blood Pressure , 2010, PPAR research.

[4]  Sabita Roy,et al.  O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .

[5]  T. Ahluwalia,et al.  ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. , 2009, DNA and cell biology.

[6]  D. Meyre,et al.  Effect of ENPP1/PC-1-K121Q and PPARgamma-Pro12Ala polymorphisms on the genetic susceptibility to T2D in the Tunisian population. , 2008, Diabetes research and clinical practice.

[7]  B. Dallapiccola,et al.  Interaction Between PPARγ2 Variants and Gender on the Modulation of Body Weight , 2008, Obesity.

[8]  M. Jois,et al.  Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance , 2008, Proceedings of the National Academy of Sciences.

[9]  J. Bressan,et al.  Polymorphism in the PPARgamma2 and beta2-adrenergic genes and diet lipid effects on body composition, energy expenditure and eating behavior of obese women , 2007, Appetite.

[10]  A. Pinto,et al.  An analysis of peroxisome proliferator-activated receptor gamma (PPAR-gamma 2) Pro12Ala polymorphism distribution and prevalence of type 2 diabetes mellitus (T2DM) in world populations in relation to dietary habits. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[11]  S. O’Rahilly,et al.  Leptin Deficiency Unmasks the Deleterious Effects of Impaired Peroxisome Proliferator–Activated Receptor γ Function (P465L PPARγ) in Mice , 2006, Diabetes.

[12]  P. Bossuyt,et al.  The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on glucose/insulin metabolism interact with prenatal exposure to famine. , 2006, Diabetes care.

[13]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[14]  R. Sacco,et al.  Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study , 2005, Diabetologia.

[15]  M. Fornage,et al.  Inverse effects of the PPAR(gamma)2 Pro12Ala polymorphism on measures of adiposity over 15 years in African Americans and whites. The CARDIA study. , 2005, Metabolism: clinical and experimental.

[16]  Eleanor Feingold,et al.  Genetic variation in fatty acid-binding protein-4 and peroxisome proliferator-activated receptor gamma interactively influence insulin sensitivity and body composition in males. , 2004, Metabolism: clinical and experimental.

[17]  M. Lazar,et al.  Transcriptional control of adipogenesis. , 2003, Annual review of nutrition.

[18]  L. Cherkas,et al.  Effect of the peroxisome proliferator activated receptor-γ gene Pro12Ala variant on body mass index: a meta-analysis , 2003, Journal of medical genetics.

[19]  M. Reilly,et al.  Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. , 2003, The Journal of clinical investigation.

[20]  G. FitzGerald,et al.  Activation of nuclear receptors by prostaglandins. , 2003, Thrombosis research.

[21]  Jimmy D Bell,et al.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.

[22]  A. Maia,et al.  The ACE insertion/deletion polymorphism is not associated with the metabolic syndrome (WHO Definition) in Brazilian type 2 diabetic patients. , 2002, Diabetes care.

[23]  M. Laakso,et al.  Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. , 2002, European journal of endocrinology.

[24]  J. Tsai,et al.  ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. , 2002, Diabetes care.

[25]  J. Olefsky.  Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .

[26]  C. Hsu,et al.  Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  S. Engeli,et al.  Physiology and pathophysiology of the adipose tissue renin-angiotensin system. , 2000, Hypertension.

[28]  A. Shuldiner,et al.  The Pro12Ala variant of peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) is associated with measures of obesity in Mexican Americans , 2000, International Journal of Obesity.

[29]  A. Solini,et al.  Polymorphisms of angiotensin-converting enzyme and angiotensinogen genes in type 2 diabetic sibships in relation to albumin excretion rate. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[31]  Jean Tichet,et al.  Gene polymorphisms of the renin‐angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study , 1998, Journal of hypertension.

[32]  K. Silver,et al.  Molecular Scanning of the Human Peroxisome Proliferator Activated Receptor γ (hPPARγ) Gene in Diabetic Caucasians: Identification of a Pro12Ala PPARγ2 Missense Mutation , 1997 .

[33]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[34]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[35]  A. Gnasso,et al.  Association between ACE-D/D polymorphism and hypertension in type II diabetic subjects. , 1994, Journal of human hypertension.

[36]  L. Tiret,et al.  Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. , 1992, American journal of human genetics.

[37]  R. Ulrich,et al.  Enhancement of adipocyte differentiation by an insulin-sensitizing agent. , 1992, Molecular pharmacology.

[38]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[39]  R. Rozen,et al.  A rapid procedure for extracting genomic DNA from leukocytes. , 1991, Nucleic acids research.

[40]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[41]  Chiao-Po Hsu,et al.  The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. , 2011, Cardiovascular Diabetology.

[42]  S. O’Rahilly,et al.  Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. , 2006, Diabetes.

[43]  A. Martí,et al.  Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents. , 2004, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[44]  C. Darimont,et al.  Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. , 2001, Endocrinology.

[45]  J. Olefsky.  Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. , 2000, The Journal of clinical investigation.

[46]  A. Shuldiner,et al.  The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. , 2000, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[47]  K. Silver,et al.  Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. , 1997, Biochemical and biophysical research communications.

[48]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[49]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.